Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

WithdrawnOBSERVATIONAL

Timeline

Start Date

November 1, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions

Diabetes Mellitus, Type 2Cardiovascular Diseases

Interventions

DRUG

empagliflozin

DRUG

metformin

DRUG

sulfonylurea

Trial Locations (1)

Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield